ReviewCirculation2024
Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?
Review in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Plant-derived extracellular vesicles as emerging cardioprotective agents for cardiovascular diseases.Journal of nanobiotechnology · 2026Review
- Beyond the Diagnosis-Personalized Risk Stratification in Contemporary Cardiovascular Medicine.Life (Basel, Switzerland) · 2026Article
- Precision cardiovascular-kidney-metabolic care - ready for prime time? A fellow's voice.American journal of preventive cardiology · 2026Article
- Resveratrol and Redox Regulation in Cardiovascular Disease Across the Life Course: Mechanistic and Translational Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Review
- Redox-Driven Precision Medicine for Life-Course Prevention of Cardiovascular-Kidney-Metabolic Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease.Nature communications · 2026Article
- Machine learning and multi-omics technologies for precision cardiovascular medicine: advancing diagnosis, risk prediction, and therapeutic guidance.Frontiers in cardiovascular medicine · 2026Review
- All-Cause and Cardiovascular Mortality Among U.S. Adults With Preclinical Heart Failure: NHANES 1999-2018.JACC. Heart failure · 2026Article
- Editorial: Immunity, atherosclerosis, and cardiovascular disease: an interdisciplinary approach to cardiometabolic health.Frontiers in cardiovascular medicine · 2026Article
- Cardiovascular Prevention: Current Gaps and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Personalized Treatment of Patients with Coronary Artery Disease: The Value and Limitations of Predictive Models.Journal of cardiovascular development and disease · 2025Review
- Cardiovascular and Metabolic Disease: New Treatment and Future Directions-The 3rd Edition.Biomedicines · 2025Article
- The Big Data Era in Cardiology and Cardiovascular Medicine: Advanced Analytics for Truly Personalized Care.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these areas are already informed by risk-assessment, but limited by the use of crude assessment tools with marginal performance. Risk assessment in prevention and population health may be improved with the use of genetics, circulating biomarkers, and imaging, leading to outcome-specific risk-prediction and enhanced phenotyping. Personalized management matching therapy to risk profile can be then implemented for either individuals or groups, improving cost-effectiveness and risk-benefit. Here, we explore this precision-like approach, including available tools, potential applications, and future perspectives for cardiovascular prevention and population health management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.